B of A Securities Maintains Underperform on PTC Therapeutics, Lowers Price Target to $23
Portfolio Pulse from Benzinga Newsdesk
B of A Securities analyst Tazeen Ahmad maintains an 'Underperform' rating on PTC Therapeutics (NASDAQ:PTCT) and has lowered the price target from $43 to $23.
September 19, 2023 | 11:09 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
PTC Therapeutics' price target has been lowered from $43 to $23 by B of A Securities, which maintains an 'Underperform' rating on the stock.
The lowering of the price target for PTC Therapeutics by B of A Securities indicates a negative outlook for the stock. This, coupled with the 'Underperform' rating, suggests that the stock may underperform in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100